Charles River Labs up on biologics services

By Staff Reporter

- Last updated on GMT

Image: iStock/patpitchaya
Image: iStock/patpitchaya

Related tags Contract research organization

Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.

The contract research organisation (CRO) reported its full year 2016 results this week, and attributed its $100m – a 13% year-on-year organic increase – in manufacturing revenues to “robust growth”​ in its microbial solutions and biologics testing business.

“Our continued investment in expanding our biologics portfolio, most recently with the acquisition of Blue Stream​, has enabled us to provide a comprehensive portfolio of both bioanalytical and biosafety testing services, with the ability to support biologic and biosimilar development from discovery through clinical phases and commercial manufacturing,”​ CEO James Foster told investors.

“This has increased the value proposition for our clients. And as demand for our services grows, we have added capacity, especially in the US.”

He added the firm views its biologics business is growing in precedence due to the growing number of biologic drugs in development.

“Our goal is to be well-positioned to capitalize on this expanding opportunity, which we believe will support our growth in the coming years.”

For the full year, Charles River reported total revenue of $1.7bn, up 23% year-on-year. The bottom line too was up 4% to $155m.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more